Xu T.,Xuzhou Medical College
Journal of Hypertension | Year: 2017
OBJECTIVE:: The optimal time to initiate antihypertensive therapy among patients with acute ischemic stroke remains uncertain. We tested the effects of blood pressure reduction among patients with acute ischemic stroke according to time from onset to initiation of antihypertensive treatment. METHODS:: We randomly assigned 4071 acute ischemic stroke patients with elevated SBP to receive antihypertensive treatment or to discontinue all antihypertensive medications during hospitalization. The primary outcome was a combination of death and major disability, and secondary outcomes included the modified Rankin score, recurrent stroke, vascular disease events, and all-cause mortality. RESULTS:: At 24?h after randomization, the differences in SBP reductions were 8.7, 9.5, and 9.6?mmHg between the antihypertensive treatment and control groups among patients receiving treatment within less than 12, 12–23, and 24–48?h after stroke onset, respectively (P?0.001 in all subgroups). At day 14 or hospital discharge, the primary and secondary outcomes were not significantly different between the treatment and control groups in all subgroups. At the 3-month follow-up, death or major disability [odds ratio (OR) 0.73; 95% confidence interval (CI) 0.55–0.96; P?=?0.03], recurrent stroke (OR 0.25; 95% CI 0.08–0.74; P?=?0.01), and vascular events (OR 0.41; 95% CI 0.18–0.95; P?=?0.04) were significantly reduced in the antihypertensive treatment group only among participants who received treatment between 24 and 48?h. CONCLUSION:: Blood pressure reduction might reduce 3-month death and major disability and recurrent stroke among patients with acute ischemic stroke who receive antihypertensive treatment between 24 and 48?h after stroke onset. TRIAL REGISTRATION:: ClinicalTrials.gov Identifier: NCT01840072 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Lv X.-P.,Xuzhou Medical College
Oncology Letters | Year: 2017
Gastrointestinal (GI) tract cancers that arise due to genetic mutations affect a large number of individuals worldwide. Even though many of the GI tract cancers arise sporadically, few of these GI tract cancers harboring a hereditary predisposition are now recognized and well characterized. These include Cowden syndrome, MUTYH-associated polyposis, hereditary pancreatic cancer, Lynch syndrome, Peutz-Jeghers syndrome, familial adenomatous polyposis (FAP), attenuated FAP, serrated polyposis syndrome, and hereditary gastric cancer. Molecular characterization of the genes that are involved in these syndromes was useful in the development of genetic testing for diagnosis and also facilitated understanding of the genetic basis of GI cancers. Current knowledge on the genetics of GI cancers with emphasis on heritability and germ line mutations forms the basis of the present review. © 2017, Spandidos Publications. All rights reserved.
Zhang P.-Y.,Xuzhou Medical College
Experimental and Therapeutic Medicine | Year: 2017
It is well recognized that the elevated plasma level of low-density lipoprotein-cholesterol (LDL-C) is a major risk factor for atherosclerosis and cardiovascular disease (CVD). Deposition of pro-atherogenic LDL-C, on the intima of arterial wall, contributes to plaque formation and atherosclerosis, which further leads to lowered blood flow to vital organs and increased risk of CVD. The most commonly used statin therapy is effective in reducing dyslipidemia and preventing cardiovascular events only in about half of the patient population. However, in patients with familial hypercholesterolemia, these drugs were not effective to meet the required goals of lower LDL-C, and to reduce the CVD risk. Furthermore, many patients even develop intolerability to statins and resistance. The identification of pro-protein convertase subtilisin/kexin type 9 (PCSK9) and the association of PCSK9 mutations with familial hypercholesterolemia led to the identification of PCSK9 as a new therapeutic target for lowering LDL-C and dyslipidemia-associated CVD. PCSK9 is found to promote the degradation of LDL-receptor (LDLR), thus rendering it unavailable for recycling to hepatocyte plasma membrane, leading to elevated levels of circulating LDL-C, as it cannot be taken up into cells. While gain-of-function mutations aggravate the degradation of LDLR as in familial hypercholesterolemia whereas loss of function mutations reduce the ability of PCSK9 to promote the degradation of LDLR and thus lower the plasma level of LDL-C and dyslipidemia. Monoclonal antibodies against PCSK9 are currently being tested in clinical trials and are found to be efficacious in countering the activity of PCSK9 and thus control the plasma LDL-C and triglycerides even in statin non-responsive patients and protect against dyslipidemia-related CVD. © 2017, Spandidos Publications. All rights reserved.
Gao C.,Xuzhou Medical College |
Tronson N.C.,University of Michigan |
Radulovic J.,Northwestern University
Neurobiology of Learning and Memory | Year: 2013
Scaffolding proteins of the neuronal post-synaptic density (PSD) are principal organizers of glutamatergic neurotransmission that bring together glutamate receptors and signaling molecules at discrete synaptic locations. Genetic alterations of individual PSD scaffolds therefore disrupt the function of entire multiprotein modules rather than a single glutamatergic mechanism, and thus induce a range of molecular and structural abnormalities in affected neurons. Despite such broad molecular consequences, knockout, knockdown, or knockin of glutamate receptor scaffolds typically affect a subset of specific behaviors and thereby mold and specialize the actions of the ubiquitous glutamatergic neurotransmitter system. Approaches designed to control the function of neuronal scaffolds may therefore have high potential to restore behavioral morbidities and comorbidities in patients with psychiatric disorders. Here we summarize a series of experiments with genetically modified mice revealing the roles of main N-methyl- d-aspartate (NMDA) and group I metabotropic glutamate (mGluR1/5) receptor scaffolds in behavior, discuss the clinical implications of the findings, and propose future research directions. © 2013 Elsevier Inc.
Sheng Z.,Tianjin First Center Hospital |
Jia X.,Xuzhou Medical College |
Kang M.,Tianjin United Family Hospital
Behavioural Brain Research | Year: 2016
Background and aim: Recent studies have suggested that use of statins was associated with risk of Parkinson's disease (PD), however, conclusions were inconsistent. Methods: A comprehensive literature search of PubMed, Web of Science, EMBASE and Cochrane Library was performed through March 2015. Studies that evaluated the association between statin use and risk of PD were included in this meta-analysis.Combined relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using a random-effects model. Subgroup analyses were also conducted. Results: A total of 11 studies(2,787,249 patients) were included for meta-analysis(5 case-control and 6 cohort studies). Our results indicated a significant risk reduction of PD(adjusted RR, 0.74, 95% CI 0.62-0.90, P < 0.001) for statin users. However, long-term statin use(RR 0.77, 95% CI 0.56-1.07, P = 0.12) and baseline low-density lipoprotein cholesterol(LDL-C) level(RR 0.58, 95% CI 0.31-1.07, P = 0.08) did not significantly affect the risk of PD. Heterogeneity and publication bias was observed in this meta-analysis (I2 = 74%, P < 0.001). Subgroup analysis showed that the difference of the study location can partly affected the pooled estimate(Asian population n = 2, adjusted RR, 0.67; 95% CI, 0.56-0.79; Western population n = 9, adjusted RR, 0.87; 95% CI, 0.80-0.95). Conclusions: Our meta-analysis suggested that statin use is associated with a reduced risk of PD. Statins might be considered as an adjuvant therapy for PD. More randomized clinical trials and observational studies are warranted. © 2016 Elsevier B.V..
Li A.,Aurora University |
Li A.,Xuzhou Medical College |
Gire D.H.,University of Washington |
Restrepo D.,Aurora University
Journal of Neuroscience | Year: 2015
Studies in different sensory systems indicate that short spike patterns within a spike train that carry items of sensory information can be extracted from the overall train by using field potential oscillations as a reference (Kayser et al., 2012; Panzeri et al., 2014). Here we test the hypothesis that the local field potential (LFP) provides the temporal reference frame needed to differentiate between odors regardless of associated outcome. Experiments were performed in the olfactory system of the mouse (Mus musculus) where the mitral/tufted (M/T) cell spike rate develops differential responses to rewarded and unrewarded odors as the animal learns to associate one of the odors with a reward in a go–no go behavioral task. We found that coherence of spiking in M/T cells with the ϒ LFP (65 to 95 Hz) differentiates between odors regardless of the associated behavioral outcome of odor presentation. © 2015 the authors.
Li J.,Nanjing University |
Li J.,Xuzhou Medical College |
Zhu J.-J.,Nanjing University
Analyst | Year: 2013
Quantum dots (QDs) have been facilitating the development of sensitive fluorescence biosensors over the past two decades due to their high quantum yield, narrow and tunable emission spectrum and good photostability. The new emerging QDs with improved biocompatibility further promote their biological applications. In this review, we first briefly introduce the prevalently used QDs and their preparation and bioconjugation approaches. Then we summarize QDs-based fluorescent biosensing for proteins and nucleic acids, and QDs-based applications in cellular and in vivo targeting and imaging. Last but not the least, we envision the potential QDs-based applications in future perspectives. This journal is © 2013 The Royal Society of Chemistry.
Li J.,Xuzhou Medical College |
Zhu J.-J.,Nanjing University |
Xu K.,Xuzhou Medical College
TrAC - Trends in Analytical Chemistry | Year: 2014
Fluorescent metal nanoclusters (NCs) are a class of emerging fluorescent materials. They have excellent photostability and biocompatibility with sub-nanometer size and are easy to synthesize. Taking advantage of these features, fluorescent metal NCs have been involved in exciting developments of analytical methods for fluorescent biosensing and bioimaging. In this review, we first summarize the approaches to synthesis and bioconjugation for fluorescent metal NCs (Ag, Au, Cu and Pt). We then highlight their applications as fluorescent probes for metal ions, small molecules, nucleic acids, and protein detection. We also summarize the use of metal NCs in cellular and in-vivo targeting and imaging. Finally, we envision the various prospects for research on fluorescent metal NCs in the future. © 2014 Elsevier Ltd.
Zhao F.C.,Xuzhou Medical College
Orthopaedic surgery | Year: 2012
To explore the clinical characteristics of osteonecrosis of the femoral head (ONFH) induced by steroids. From January 2000 to October 2009, 497 hips in 270 cases of ONFH induced by steroids were studied. A questionnaire was administered when the patients were admitted; the questions concerned the underlying disease, duration of steroid usage, total dosage of steroid, incubation period (time interval between commencement of steroid therapy and onset of pain), severity of pain, location of initial complaint, primary diagnosis, time lag from onset of pain to final diagnosis and physical signs when admitted. The correlations between pain and Association Research Circulation Osseous (ARCO) stage, bone marrow edema (BME) and lesion size were analyzed. The median of time between commencing steroid medication and developing ONFH for the 269 cases was 18 months (range, 2-384 months). 78.82% cases presented with pain within three years of steroid initiation, only 10.41% patients first complained of pain six or more years after commencing steroid therapy. Fifty-six cases (20.82%) were misdiagnosed, lumbar disorders being the most frequent misdiagnoses. 79.29% of symptomatic hips presented with abnormal physical tests. Of 420 symptomatic hips, 166 hips were type C1, 223 hips type C2; 299 hips had collapsed; and there was BME in 209 hips. Most patients with ONFH induced by steroids complained of pain within 3 years of commencing steroid therapy. Pain was associated with lesion size, collapse and BME. Atypical location of pain, failure to perform a physical examination and MRI findings were the main causes of misdiagnoses. © 2012 Tianjin Hospital and Blackwell Publishing Asia Pty Ltd.
Zhao X.,Xuzhou Medical College
Endocrine Journal | Year: 2014
Strategies for increasing functional beta cell mass are effective for diabetes therapy. Although controversy remains on the existence of facultative beta cell progenitors in the adult pancreas, most evidence does not support such a possibility. One of the greatest physiological increases in beta cells has been detected in the maternal pancreas during pregnancy, following neonatal period and in the setting of insulin resistance. However, no systematical analysis on the beta cell growth in this period has been ever performed. Here we analyzed beta cell replication by quantifying BrdU incorporated beta cells at different time points in the pregnant mice. Similarly, we evaluated the possible involvement of beta cell neogenesis (differentiation from progenitor cells) by analyzing expression of Neurog3, a key determinant of pancreatic endocrine cell neogenesis during embryogenesis, in the exocrine pancreas. We found a dynamic increase in beta cell replication, but failed to detect beta cell neogenesis, demonstrating that beta cell growth in the maternal pancreas during pregnancy is predominantly attributable to beta cell replication, rather than beta cell neogenesis. © The Japan Endocrine Society.